| Relationship Between Apparent Systemic Clearance of Vemurafenib and Toxicity in Patients With Melanoma.J Clin Pharmacol | PMID 33908053无 PMCID | 2021-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent.J Clin Pharmacol | PMID 33908635PMC8457124 | 2021-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC.J Thorac Oncol | PMID 33915251无 PMCID | 2021-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial.Lancet Infect Dis | PMID 33989539无 PMCID | 2021-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response.Cephalalgia | PMID 33990144PMC8411464 | 2021-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Should Vitamin A Injections to Prevent Bronchopulmonary Dysplasia or Death Be Reserved for High-Risk Infants? Reanalysis of the National Institute of Child Health and Human Development Neonatal Research Network Randomized Trial.J Pediatr | PMID 34004189PMC8403138 | 2021-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706).J Thorac Oncol | PMID 34033974无 PMCID | 2021-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial.J Thorac Oncol | PMID 34033975无 PMCID | 2021-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12).J Thorac Oncol | PMID 34048947无 PMCID | 2021-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension.Int J Urol | PMID 34075630PMC8453759 | 2021-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma.Ann Oncol | PMID 34082019无 PMCID | 2021-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.Cancer Chemother Pharmacol | PMID 34106303PMC8187458 | 2021-Sep | 0.85 | The record describes a Phase III randomized trial in HER2-positive early breast cancer with a drug intervention (pertuzumab and trastuzumab). However, the primary analysis is pharmacokinetic and exposure-response (safety and pathologic complete response rate), which are not time-to-event efficacy endpoints (OS, PFS, DFS, etc.). The study lacks a primary or key secondary time-to-event endpoint. | 待处理 |
| Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.Clin Lymphoma Myeloma Leuk | PMID 34108127无 PMCID | 2021-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.Ann Oncol | PMID 34116144无 PMCID | 2021-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention.AIDS Behav | PMID 34117592PMC8577988 | 2021-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.Ann Oncol | PMID 34139272无 PMCID | 2021-Sep | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial.Eur Urol | PMID 34140144无 PMCID | 2021-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Revisiting the JOQUER trial: stratification of primary Sjögren's syndrome and the clinical and interferon response to hydroxychloroquine.Rheumatol Int | PMID 34165604PMC8316226 | 2021-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A medicine adoption model for assessing the expected effects of additional real-world evidence (RWE) at product launch.Curr Med Res Opin | PMID 34176383无 PMCID | 2021-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19.Adv Sci (Weinh) | PMID 34180141PMC8420376 | 2021-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.Cancer Commun (Lond) | PMID 34184418PMC8441057 | 2021-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy of ready-to-use therapeutic food in malnourished children with cancer: Results of a randomized, open-label phase 3 trial.Pediatr Blood Cancer | PMID 34212474无 PMCID | 2021-Sep | 0.95 | The study is a randomized Phase III trial in pediatric cancer with original results, but it evaluates a nutritional intervention (RUTF), not a drug, and its primary/secondary outcomes are not time-to-event efficacy endpoints (e.g., OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR analyses). | 待处理 |
| Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial.Eur J Cancer | PMID 34225066无 PMCID | 2021-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial.Thorac Cancer | PMID 34273139PMC8410552 | 2021-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.Eur J Cancer | PMID 34273811无 PMCID | 2021-Sep | 0.95 | This is an analysis of health-related quality of life outcomes from the ARAMIS trial. While the parent trial was a Phase III randomized trial with a drug intervention and MFS/OS as primary/key secondary endpoints, this specific report focuses solely on patient-reported quality-of-life endpoints (time to deterioration on FACT-P and EORTC QLQ-PR25). It is therefore a quality-of-life analysis and does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint for inclusion. | 待处理 |
| Economic Impact of Preoperative Meloxicam IV Administration in Total Knee Arthroplasty: A Randomized Trial Sub-Study.J Pain Palliat Care Pharmacother | PMID 34280067无 PMCID | 2021-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.Lancet Respir Med | PMID 34280355无 PMCID | 2021-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Diabetes Endocrinol | PMID 34302745PMC8294807 | 2021-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.Eur J Cancer | PMID 34304054无 PMCID | 2021-Sep | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial.Lancet Oncol | PMID 34329606PMC8416799 | 2021-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.Nat Med | PMID 34341578无 PMCID | 2021-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.Lancet Oncol | PMID 34363762无 PMCID | 2021-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network.Eur J Cancer | PMID 34371442无 PMCID | 2021-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial.J Gynecol Oncol | PMID 34378365PMC8362816 | 2021-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.Am J Clin Dermatol | PMID 34406619PMC8370859 | 2021-Sep | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Budesonide as induction therapy for incomplete microscopic colitis: A randomised, placebo-controlled multicentre trial.United European Gastroenterol J | PMID 34414678PMC8435258 | 2021-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effects of Fixed-dose Combination of Low-intensity Rosuvastatin and Ezetimibe Versus Moderate-intensity Rosuvastatin Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia: A Randomized, Double-blind, Multicenter, Phase III Study.Clin Ther | PMID 34429197无 PMCID | 2021-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.Lancet Haematol | PMID 34450102无 PMCID | 2021-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial.Paediatr Drugs | PMID 34462864PMC8418591 | 2021-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.Contemp Clin Trials | PMID 34538402PMC8520913 | 2021-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension.RMD Open | PMID 34548383PMC8458321 | 2021-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study).Jpn J Clin Oncol | PMID 34215870无 PMCID | 2021-Aug-30 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy.Jpn J Clin Oncol | PMID 34322703PMC8405845 | 2021-Aug-30 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A pilot feasibility study of gabapentin for managing pain in children with dystonic cerebral palsy.BMC Pediatr | PMID 34454442PMC8401181 | 2021-Aug-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.J Hematol Oncol | PMID 34454540PMC8401338 | 2021-Aug-28 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.Lancet | PMID 34454674无 PMCID | 2021-Aug-28 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Roxadustat for anemia in patients with end-stage renal disease incident to dialysis.Nephrol Dial Transplant | PMID 33629100无 PMCID | 2021-Aug-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).Nephrol Dial Transplant | PMID 33630072PMC8397511 | 2021-Aug-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.N Engl J Med | PMID 34437784PMC8982185 | 2021-Aug-26 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy.Arthritis Res Ther | PMID 34429160PMC8383419 | 2021-Aug-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |